NCT03744546No Longer Available不适用
Expanded Access to ABBV-8E12
AbbVie0 个研究点开始时间: 2018年11月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access to ABBV-787Acute Myeloid LeukemiaNCT06439966AbbVie
Available
不适用
Expanded Access to Telisotuzumab AdizutecanNCT05982873AbbVie
No Longer Available
不适用
Expanded Access to ABT-414Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) DiagnosisNCT03123952AbbVie
Available
不适用
Expanded Access to ABBV-CLS-484Advanced Solid Tumor CancerNCT06188975Calico Life Sciences LLC
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie
